| pubmed-article:21271613 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0217843 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:21271613 | lifeskim:mentions | umls-concept:C2713006 | lld:lifeskim |
| pubmed-article:21271613 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:21271613 | pubmed:dateCreated | 2011-7-25 | lld:pubmed |
| pubmed-article:21271613 | pubmed:abstractText | This two-part study assessed the safety and tolerability of combined treatment with zibotentan (ZD4054), a specific endothelin A receptor antagonist, plus docetaxel in patients with metastatic castration-resistant prostate cancer. | lld:pubmed |
| pubmed-article:21271613 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21271613 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21271613 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21271613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21271613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21271613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21271613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21271613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21271613 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21271613 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21271613 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:21271613 | pubmed:issn | 1097-0045 | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:MillerKurtK | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:BurrisHoward... | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:TrumpDonald... | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:PayneHeatherH | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:MorrisThomasT | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:NathanFaithF | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:TaboadaMariaM | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:StephensonJoe... | lld:pubmed |
| pubmed-article:21271613 | pubmed:author | pubmed-author:HubnerAndreas... | lld:pubmed |
| pubmed-article:21271613 | pubmed:copyrightInfo | Copyright © 2011 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:21271613 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21271613 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:21271613 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21271613 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21271613 | pubmed:pagination | 1264-75 | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:meshHeading | pubmed-meshheading:21271613... | lld:pubmed |
| pubmed-article:21271613 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21271613 | pubmed:articleTitle | Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. | lld:pubmed |
| pubmed-article:21271613 | pubmed:affiliation | Roswell Park Cancer Institute, Buffalo, NY, USA. donald.trump@roswellpark.org | lld:pubmed |
| pubmed-article:21271613 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21271613 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21271613 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21271613 | pubmed:publicationType | Multicenter Study | lld:pubmed |
